文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

大规模根除幽门螺杆菌以降低胃癌发病率和死亡率:马祖列岛长期队列研究

Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands.
PubMed 文献 · Gut · 2020-08-13

本研究在台湾马祖列岛30岁以上幽门螺杆菌高感染人群中进行2004至2018年大规模根除治疗,评估其对胃癌发病率和死亡率的影响。经过六轮筛查和治疗,幽门螺杆菌感染率从64.2%降至15.0%,与1995-2003年历史对照相比,胃癌发病率降低53%(95%CI 30%至69%,p<0.001),死亡率降低25%(95%CI -14%至51%,p=0.18)。结论认为人群根除幽门螺杆菌显著降低胃癌发病率且未增加不良后果,死亡率降低可能需要更长随访。

要点

  • 六轮筛查根除后幽门螺杆菌感染率从64.2%降至15.0%,再感染率低于每人年1%。
  • 与历史对照相比胃癌发病率降低53%(95%CI 30%至69%,p<0.001)。
  • 胃癌死亡率降低25%(95%CI -14%至51%,p=0.18),未达统计学显著。

核心结论

  • 人群根除幽门螺杆菌显著降低胃癌发病率,且未增加不良后果。
  • 死亡率显著降低可能需要更长随访期。

研究设计与样本

  • 在台湾马祖列岛30岁以上幽门螺杆菌高感染人群中,于2004年至2018年开展大规模根除。
  • 13C尿素呼气试验阳性者接受根除治疗。
  • 评估至2016年底的胃癌发病率和至2018年底的胃癌死亡率。

主要发现

  • 六轮筛查根除后覆盖率达85.5%(6512/7616)。
  • 治疗转介率为93.5%(4286/4584)。
  • 幽门螺杆菌感染率从64.2%降至15.0%,再感染率低于每人年1%。
  • 萎缩性胃炎和肠上皮化生的存在与严重程度随时间降低。
  • 与1995-2003年历史对照相比,化学预防期间胃癌发病率降低53%(95%CI 30%至69%,p<0.001),死亡率降低25%(95%CI -14%至51%,p=0.18)。

局限性

  • 死亡率降低的95%CI为-14%至51%,未达统计学显著,原文认为需更长随访期才可能实现显著降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although mass eradication of Helicobacter pylori has been proposed as a means to eliminate gastric cancer, its long-term effects remain unclear. DESIGN: Mass eradication of H. pylori infection was launched in 2004 and continued until 2018 for a high-risk Taiwanese population aged 30 years or older dwelling on Matsu Islands with prevalent H. pylori infection. Test positives for the 13C-urea breath test underwent eradication therapy. We evaluated the effectiveness of the mass eradication in reducing two main outcomes, incidence and mortality rates of gastric cancer, until the end of 2016 and 2018, respectively. RESULTS: After six rounds of mass screening and eradication, the coverage rate reached 85.5% (6512/7616). The referral rate for treatment was 93.5% (4286/4584). The prevalence rates of H. pylori fell from 64.2% to 15.0% with reinfection rates of less than 1% per person-year. The presence and severity of atrophic gastritis and intestinal metaplasia also decreased with time. Compared with the historical control period from 1995 to 2003, the effectiveness in reducing gastric cancer incidence and mortality during the chemoprevention period was 53% (95% CI 30% to 69%, p<0.001) and 25% (95% CI -14% to 51%, p=0.18), respectively. No significant changes were noted in the incidence rates of other digestive tract cancers or the antibiotic resistance rate of H. pylori. CONCLUSION: Population-based eradication of H. pylori has significantly reduced gastric cancer incidence with no increase in the likelihood of adverse consequences. A significant reduction in mortality is likely to be achieved with a longer follow-up period. TRIAL REGISTRATION NUMBER: NCT00155389.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Chiang TH, Chang WJ, Chen SL, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2020. PMID: 32792335. doi:10.1136/gutjnl-2020-322200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。